H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Key takeaways
- The trial showed that past exposure to numerous advanced medicines did not significantly reduce treatment benefit.
- Wainwright, this shows that FcRn acts differently from JAK/TNF-directed treatments.
- Wainwright upgraded the chance of success for IMVT-1402 in rheumatoid arthritis from 30% to 55%, as well as its EV sales multiple from 9x to 10x.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data Sheryar Siddiq Tue, June 2, 2026 at 4:38 PM GMT+7 2 min read IMVT Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to invest in. On May 21, H.C. Wainwright boosted Immunovant, Inc. (NASDAQ:IMVT)’s price objective to $40 from $35, keeping a Buy rating on the company’s shares. The firm noted high response rates from its Phase 2 rheumatoid arthritis trial.
The trial showed that past exposure to numerous advanced medicines did not significantly reduce treatment benefit.
According to H.C. Wainwright, this shows that FcRn acts differently from JAK/TNF-directed treatments. According to the firm, RA response rates often fall as patients go through various medications, especially after JAK inhibitors.